Sign Up to like & get
recommendations!
2
Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34619
Abstract: In the year 2021, there were three new Food and Drug Administration approvals for all leukemia types: asciminib (Scemblix) for chronic myeloid leukemia, brexucabtagene autoleucel (Tecartus) for relapsed/refractory B‐cell acute lymphocytic leukemia, and asparaginase erwinia…
read more here.
Keywords:
top advances;
leukemia;
advances year;
brexucabtagene autoleucel ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01797
Abstract: PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II ZUMA-2 trial,…
read more here.
Keywords:
cell;
standard care;
brexu cel;
relapsed refractory ... See more keywords